Physician profile
Kevin L Schewe
NPI 1902883952
$50,987.57
in general payments reported to CMS, 2019-2025
46 companies · $930 in 2025
The $930 reported for 2025 was more than what 82% of Radiation Oncology providers received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $24K · 2020: $24K · 2022: $163 · 2023: $632 · 2024: $1,055 · 2025: $930.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,617.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,616.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sensus Healthcare, INC. | $48,000.00 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $345.83 | 2023-2025 | Keytruda, Welireg, Reblozyl |
| Novartis Pharmaceuticals Corporation | $284.37 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $226.48 | 2022-2025 | Tagrisso, Enhertu, Lynparza |
| Janssen Biotech, INC. | $187.29 | 2022-2025 | Erleada, Balversa, Akeega |
| Pfizer INC. | $133.44 | 2023-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $132.13 | 2019-2023 | |
| Genentech USA, INC. | $110.35 | 2023-2025 | Polivy, Lunsumio, Columvi |
| Daiichi Sankyo INC. | $104.53 | 2024-2025 | Enhertu, Datroway |
| Genmab U.S., INC. | $99.69 | 2023-2025 | Tivdak, Epkinly |
| Incyte Corporation | $93.80 | 2023-2025 | Jakafi, Monjuvi, Pemazyre |
| Takeda Pharmaceuticals U.S.A., INC. | $86.42 | 2024-2025 | Fruzaqla |
| Eisai INC. | $85.14 | 2024-2025 | |
| Kyowa Kirin, INC. | $77.56 | 2019-2024 | Poteligeo |
| Sun Pharmaceutical Industries INC. | $70.79 | 2023-2024 | Yonsa, Odomzo |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kevin Schewe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.